Expert Insight
Patient Access Barriers Drive GLP-1 Development Strategies
At Nordic Life Science Days (NLSDays), leading pharmaceutical executives from Novo Nordisk, AstraZeneca, and Roche convened to discuss the evolving landscape of cardiovascular, renal, and metabolic (CVRM) drug development. The “Transforming CVRM Health” panel revealed that despite clinical successes with
29 October 2025